Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D. Zimmer L, et al. Among authors: vaubel j. PLoS One. 2015 Mar 11;10(3):e0118564. doi: 10.1371/journal.pone.0118564. eCollection 2015. PLoS One. 2015. PMID: 25761109 Free PMC article. Clinical Trial.
Current advances and perspectives in the treatment of advanced melanoma.
Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Livingstone E, et al. Among authors: vaubel j. J Dtsch Dermatol Ges. 2012 May;10(5):319-25. doi: 10.1111/j.1610-0387.2012.07895.x. Epub 2012 Mar 20. J Dtsch Dermatol Ges. 2012. PMID: 22432863 Free article. Review.
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM. Voskens CJ, et al. Among authors: vaubel j. PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14. PLoS One. 2013. PMID: 23341990 Free PMC article.
Advances and perspectives in immunotherapy of melanoma.
Schadendorf D, Vaubel J, Livingstone E, Zimmer L. Schadendorf D, et al. Among authors: vaubel j. Ann Oncol. 2012 Sep;23 Suppl 10:x104-8. doi: 10.1093/annonc/mds321. Ann Oncol. 2012. PMID: 22987943 Free article.
Side effects of systemic oncological therapies in dermatology.
Zimmer L, Vaubel J, Livingstone E, Schadendorf D. Zimmer L, et al. Among authors: vaubel j. J Dtsch Dermatol Ges. 2012 Jul;10(7):475-86. doi: 10.1111/j.1610-0387.2012.07942.x. Epub 2012 May 9. J Dtsch Dermatol Ges. 2012. PMID: 22571234 Free article. Review. English, German.
Adjuvant pegylated interferon α-2b therapy for melanoma.
Schilling B, Vaubel J, Schadendorf D. Schilling B, et al. Among authors: vaubel j. Oncol Lett. 2010 Mar;1(2):237-241. doi: 10.3892/ol_00000042. Epub 2010 Mar 1. Oncol Lett. 2010. PMID: 22966287 Free PMC article.
[Immunotherapy of melanomas].
Zimmer L, Vaubel J, Schadendorf D. Zimmer L, et al. Among authors: vaubel j. Hautarzt. 2012 Dec;63(12):952-8. doi: 10.1007/s00105-012-2470-4. Hautarzt. 2012. PMID: 23097082 Review. German.
12 results